Takeda Pharmaceutical Company Limited (TAK)

13.36 -0.01 (-0.07%) 收市：04:00PM EDT

Takeda Pharmaceutical Company Limited

1-1, Nihonbashi-Honcho 2-chome
Chuo-ku
Tokyo 103-8668
Japan
81 3 3278 2111
https://www.takeda.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 49,095

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Christophe Weber	President, CEO & Representative Director	3.74M	無	1966
Dr. Andrew S. Plump	President of Research & Development and Representative Director	2.67M	無	1965
Dr. Seigo Izumo	Chair of Management Board	無	無	無
Mr. Milano Furuta	Chief Financial Officer	無	無	1978
Mr. Haruhiko Hirate	Member of Management Board	無	無	1957
Mr. Salvatore Alesci M.D., Ph.D.	Member of Management Board and Head of R&D Global Science & Biomedical Policy	無	無	1975
Norimasa Takeda	Chief Accounting Officer & Corporate Controller	無	無	無
Mr. Iwaaki Taniguchi	Senior Vice President of Corporate Finance & Controlling Department	無	無	無
Mr. Gabriele Ricci	Chief Data & Technology Officer	無	無	1978
Mr. Christopher David O'Reilly	Global Head of Investor Relations & Global Finance	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

公司管治

截至 2024年5月1日 止，Takeda Pharmaceutical Company Limited 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：1；董事會：1；股東權利：5；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。